Sigma Of Australia Battle Over Effexor Eyed Closely By Others
This article was originally published in PharmAsia News
Australia's Sigma Pharmaceutical and its attempts to break loose of Wyeth's Effexor (venlafaxine) antidepressant are being watched closely by other generics makers as Sigma wages its patent battles. Effexor is the best-selling antidepressant in Australia and Sigma has lost its first court challenge to break the patent. Sigma faces two other patents Wyeth claims for the drug. Other generics makers seek to market the drug in Australia where the national health plan shelled out about $80.7 million for it last year. (Click here for more
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.